News & Opinion
An editorial in The Scientist (free, but registration required to access) discusses this rather shady practice- ie of failing to cite relevant papers. The writer, Richard Gallagher, raises an interesting point that“the openness gifted us by the Internet is revealing the lax standards that have been in place all the time. “- one that could easily be made of many other dubious publication practices.
A news feature in Nature Biotechnology (subscription required for full text) discusses the potential perils of academia and companies getting into bed with each other in these financially straightened times, and the need for especially careful management of competing interests.
A story that has receive extensive coverage over the past few weeks on the web is of a series of allegedly "fake" journals which were revealed during a court case in Australia concerning marketing of the drug Vioxx.
A BMJ editorial discusses the recent FDA ruling that clinical trials performed outside the US no longerhave to conform to the Declaration of Helsinki if used to supportapplications for registration of products in the US but that the regulatory standard expected is that of the International Conference on Harmonisation Good Clinical
This report apparently focuses on financial conflict of interests, especially where there is a potential for patient harm.
An editorial in American Journal of Health-System Pharmacy describes the outcome of a legal action against their journal from a manufacturer who claimed that an article (abstract only, full text requires a subscription) published in the 15 March 2007 issue of AJHP defamed the manufacturer "through the criticism and test results published in the article" as the manufacturer's prod
The full piece, published on March 26th, which describes the operation as being a "congressional sting operation" is here, excerpt:
"The sting, detailed at a House Energy and Commerce Committee hearing Thursday, involved the creation of a fictitious company and a fake medical device, a surgical adhesive gel. The sham firm then applied to three for-profit oversight groups — called institutional review boards, or IRBs — for approval to begin a clinical trial using their adhesive on human subjects."
An editorial in JAMA1 describes a case of an author’s undeclared conflict of interest which was reported to the journal by a reader, Jonathan Leo. The reason for the editorial (in addition to a published correction) is that Leo sent a copy of his letter to the New York Times and also posted his concerns in a BMJ Rapid Response2 which appeared before JAMA published its correction in its print issue of March 11.